Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 August 2003

Hepatitis C virus RNA level changes in sera during different regimens of treatment in patients with chronic hepatitis C

Włodzimierz Mazur, Maciej Gonciarz, Urszula Mazurek, Magdalena Jurzak, Tadeusz Wilczok, Zbigniew Gonciarz

Med Sci Monit 2003; 9(3): 39-43 :: ID: 428598


Interferon alfa-2b (IFN) has been shown to be effective for chronic hepatitis C infection, but treatment efficacy is still limited. Sustained response after intrerferon alfa monotherapy is achieved in about 15-25%. Great efforts are made to identify more effective forms of therapy. Some of them include modifications of dosage of antiviral drugs, duration of the therapy and more optimal selection of patients for the treatment. Several virus- and host-related predictive factors for response to antiviral treatment have been proposed. One of the key predictive factors of sustained response to therapy are the pretreatment levels of viremia as well as the dynamics of initial changes of HCV-RNA levels assessed during antiviral therapy. Aim. The aim of our study was to compare changes of HCV-RNA viremia in patients with chronic hepatitis C during different regimens of antiviral treatment. Material/Methods: 21 patients chronically infected with HCV (anti-HCV positive, HCV-RNA positive by PCR) were enrolled in the study. 11 patients (Group I) were treated with interferon alfa-2b (IFN-a2b) at 3 MU tiw doses administered subcutaneously for 12 months. 10 patients (Group II) received 3 MU of IFN-a2b daily during the first month and later the treatment was continued with the same dosage tiw for the next 11 months. The response to the treatment was assessed according to the generally accepted criteria after 6-month follow-up. The initial decline of HCV-RNA after 4 weeks of therapy was assessed. Results: Results are presented in the Table. HCV-RNA expressed in copy/ml. Conclusions: The initial decline of HCV-RNA level during the first 4 weeks of antiviral therapy with interferon correlates with the final response to the treatment. The greater decline of viremia was observed in the group of patients treated with the “induction” variant of treatment.

Keywords: chronic hepatitis C, Interferon Alfa-2b, HCV-RNA viremia

Add Comment 0 Comments


01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204


In Press

15 Jan 2024 : Clinical Research  

Comparison of Modified Shock Index and Shock Index for Predicting Massive Transfusion in Women with Primary...

Med Sci Monit In Press; DOI: 10.12659/MSM.943286  

15 Jan 2024 : Database Analysis  

Bibliometric Analysis of Brain Stimulation Technologies in Sleep Disorders

Med Sci Monit In Press; DOI: 10.12659/MSM.942687  

15 Jan 2024 : Clinical Research  

Clinical Outcomes of Arthroscopic Surgery in Patients with Gluteal Muscle Contracture: Single-Institution R...

Med Sci Monit In Press; DOI: 10.12659/MSM.942945  

17 Jan 2024 : Laboratory Research  

Impact of Auxiliary Features on Retention of Short Dental Crowns: An In-Vitro Analysis of Box and Groove Pr...

Med Sci Monit In Press; DOI: 10.12659/MSM.943401  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750